Viracta Therapeutics Inc. (NASDAQ: VIRX)
$0.55
+0.0110 ( +2.04% ) 66.4K
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Market Data
Open
$0.55
Previous close
$0.54
Volume
66.4K
Market cap
$20.85M
Day range
$0.53 - $0.56
52 week range
$0.43 - $1.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 11 | May 31, 2024 |
4 | Insider transactions | 2 | May 29, 2024 |
4 | Insider transactions | 2 | May 29, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |
3 | Insider transactions | 2 | May 16, 2024 |
8-k | 8K-related | 13 | May 14, 2024 |
10-q | Quarterly Reports | 49 | May 09, 2024 |
8-k | 8K-related | 12 | May 09, 2024 |
def | Proxies and info statements | 11 | Apr 26, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |